Investment
Features
FeesSafety
Academy
More
Pluang+

Visara licenses VIS-102, a new therapy for neurotrophic keratitis, expanding its eye disease treatment pipeline.

Company Fundamentals
13 Oct 2026
GlobeNewsWire
View Source
Bullish
Visara licenses VIS-102, a new therapy for neurotrophic keratitis, expanding its eye disease treatment pipeline.

Visara, a subsidiary of NovaBridge Biosciences, has secured exclusive global rights (excluding Greater China) to develop and commercialize VIS-102, an investigational nerve growth factor therapy for neurotrophic keratitis (NK). VIS-102 aims to restore corneal health with a more convenient, ready-to-use single-dose format, potentially easing treatment burdens for patients. Early clinical data showed promising corneal healing results, supporting further development. This move broadens Visara's ophthalmology portfolio beyond retinal diseases into ocular surface disorders, marking a strategic expansion in its pipeline.

Visara's expansion in ophthalmology with a new nerve growth factor therapy for neurotrophic keratitis is the subject here, with Pluang's health sector market data providing context. As of Oct 13, 2026 18:02 WIB, out of 128 priced health-sector US stocks tradable on Pluang, 78 rose and 41 fell. Notable movers include NBIX at USD 139.05 with a 1-day change of -1.64% and 100% sell order activity, SNY at USD 40.37 with a 1.59% gain and 74% buy order activity, and CGC at USD 0.75 with a -1.58% change and 65% buy order activity.

More News

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...

Analyst Insights
Bullish
47 minutes ago
Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...

Company Fundamentals
Bullish
56 minutes ago
TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC's preliminary Q3 2026 revenue reached approximately NT$1.49 trillion, about 50% higher year-over-year and above management guidance, driven by strong AI chip demand. The company holds a dominant 73% share of the global pure-play foundry market, ...

Company Fundamentals
Bullish
1 hour ago
Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey have launched Growth Signals, a new initiative to regularly poll entrepreneurs and business leaders of fast-growing companies. This program aims to capture their priorities, challenges, and growth outlook to inform Inc.'s editor...

Others
Neutral
1 hour ago
BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard Corporation has launched a new corporate website featuring an expanded treasury dashboard that updates its Adjusted Net Asset Value and other key financial metrics intraday. This move aims to increase transparency and accountability in t...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App